The adult and the maternal and child health SAMMEC software modules were used to estimate SAM, YPLL, and productivity losses attributed to diseases caused by smoking. Sex-and age-specific smoking-attributable deaths were calculated by multiplying the total number of deaths for 19 adult and four infant disease categories (Table) by estimates of the smoking-attributable fraction (SAF) † of preventable deaths. The attributable fractions provide estimates of the public health burden of each risk factor and the relative importance of risk factors for multifactorial diseases. Because of the effect of interactions between various risk factors, attributable fractions for a given disease can total more than 100%. For adults, SAFs were derived using sex-specific relative risk (RR) estimates from the American Cancer Society's Cancer Prevention Study-II (CPS-II) for current and former smokers for each cause of death for the period 1982--1988. For ischemic heart disease and cerebrovascular disease deaths, RR estimates also were stratified by age (35--64 years and >65 years). Sex-and age-specific (35--64 years and >65 years) current and former cigarette smoking prevalence estimates from the National Health Interview Survey also were used to calculate SAFs. For infants, SAFs were calculated by using pediatric RR estimates and maternal smoking prevalence estimates from birth certificates. Smokingattributable YPLL and productivity losses were estimated by multiplying sex-and age-specific SAM by remaining life expectancy (5) and lifetime earnings data (6) . In addition, smoking-attributable residential fire-related deaths (7) and lung cancer and heart disease deaths attributable to exposure to secondhand smoke (8, 9) were included in the SAM, but not in YPLL and productivity loss estimates. (2) . The number of smoking-attributable deaths varies according to trends in smoking prevalence and the number of deaths from diseases caused by smoking. SAM estimates also change when a causal relationship is established between smoking and a disease not previously included in SAMMEC (1). Although smoking prevalence has declined dramatically since its peak in the 1960s, the number of smoking-attributable deaths has remained relatively unchanged, primarily because of increases in population size (particularly among older age groups). Even with declines in the rates of various smoking-related diseases (e.g., coronary heart disease), the absolute number of deaths is increasing as the total population increases. In addition, cohorts of smokers with the highest peak prevalence have now reached the ages with the highest incidence of smoking-attributable diseases.
The relative risk estimates used in the calculation of SAM have remained the same. In general, the magnitude of the relationship between smoking and the diseases it causes has remained stable over time (1) . However, CDC is continuing to monitor whether the RRs for smoking are changing over time. Future SAMMEC estimates might contain updated RRs, particularly for females, because their adoption of smoking (and hence their duration of smoking) lagged that of males during the early to mid-1900s. Prevalence of smoking among females peaked in the 1960s and in recent cohorts of smokers more closely follows the trend for male smokers. Smoking-attributable fractions are higher for cancers and COPD than for cardiovascular diseases; however, because the absolute number of deaths is highest for coronary heart disease, it contributes a large number of smoking-attributable deaths.
Preventing smoking and increasing cessation rates need to remain priorities of Smoking-Attributable Mortality, Years of Potential Life Lost... http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm public health professionals who are working to prevent heart disease and stroke. Dramatic declines in smoking-attributable deaths can be achieved by further reducing smoking prevalence rates. Leading causes of death, such as lung cancer and COPD, could become relatively uncommon in future generations if the prevalence of smoking was substantially reduced (1,3).
The findings in this report are subject to at least six limitations. First, the estimates understate deaths attributable to tobacco use because estimates of deaths attributable to cigar smoking, pipe smoking, and smokeless tobacco use were excluded. Although the overall prevalence rates of cigar and pipe smoking and use of smokeless tobacco have remained relatively stable, increased public health concerns about these products might warrant including estimates of deaths attributable to these tobacco products in the future. Second, RRs were based on deaths during 1982--1988 among birth cohorts who might have had different smoking histories than current or former smokers (e.g., age of initiation and duration of smoking before quitting). Third, this report used a deathcertificate--based definition of COPD, including codes for bronchitis/emphysema and chronic airway obstruction (ICD-10 J44) (1). Therefore, the COPD SAM estimate used for this report might differ from other estimates that use other definitions of COPD (1). Fourth, RRs were adjusted for the effects of age but not for other potential confounders. However, research suggests that education, alcohol, and other confounders had negligible additional effects on SAM estimates for lung cancer, COPD, ischemic heart disease, and cerebrovascular disease in CPS-II. Fifth, productivity losses understate the total costs of smoking because costs associated with smoking-attributable health-care expenditures, smoking-related disability, employee absenteeism, and secondhand-smoke--attributable disease morbidity and mortality were not included. Finally, the estimates do not account for the sampling variability in smoking prevalence estimates or RRs.
Cigarette smoking continues to impose substantial health and financial costs on society. 
